Life-Changing drug access extended for asthma and rare disease patients
NCT ID NCT07444567
Summary
This study provides continued access to the medication benralizumab (Fasenra) for people with asthma, EGPA, or HES who completed a previous clinical trial and are still benefiting from the treatment. It aims to monitor the long-term safety of the drug while allowing participants to keep receiving it. The study is open to about 230 people who cannot get the medication through regular commercial channels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.